Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine

Journal of Internal Medicine

Volumn 271, Issue 2, 2012, Pages 111-121

  Tian, Q ^a   Price, N D ^a   Hood, L ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Blood biomarkers; Cancer complexity; Molecular diagnostics; P4 medicine; Quantized cell populations; Systems medicine

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTOME;

BLOOD; CANCER RESEARCH; CLINICAL EVALUATION; CONFERENCE PAPER; DNA DETERMINATION; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE SEQUENCE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; LEIOMYOSARCOMA; MEDICAL PRACTICE; MICROFLUIDIC ANALYSIS; MOLECULAR DIAGNOSIS; NEOPLASM; NONHUMAN; ONCOLOGY; PHENOTYPE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SINGLE CELL ANALYSIS; SOCIETY; SYSTEMS BIOLOGY; WELLBEING;

GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; MUTATION; NEOPLASMS; PROTEOMICS; SINGLE-CELL ANALYSIS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84855929701     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02498.x     Document Type: Conference Paper

References (48)

1. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011; 8: 184-7.
2. Price ND, Edelman LB, Lee I et al. Systems biology and systems medicine. In: Ginsburg G, Willard H, eds. Genomic and Personalized Medicine: From Principles to Practice. Amsterdam: Elsevier, 2009; 131-41.
3. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-3.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Lin B, White JT, Lu W et al. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005; 65: 3081-91.
6. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357: 258-65.
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
8. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
9. Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305-15.
10. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
11. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-33.
12. Ley TJ, Mardis ER, Ding L et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
13. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-66.
14. Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-72.
15. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-6.
16. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-7.
17. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA et al. Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 2006; 103: 18238-42.
18. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol 2010; 5: 51-75.
19. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011; 11: 450-7.
20. Davidson EH, Levine MS. Properties of developmental gene regulatory networks. Proc Natl Acad Sci U S A 2008; 105: 20063-6.
21. Cahoy JD, Emery B, Kaushal A et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008; 28: 264-78.
22. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
24. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
25. Chow LM, Endersby R, Zhu X et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011; 19: 305-16.
26. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
27. Roach JC, Glusman G, Smit AF et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010; 328: 636-9.
28. Ideker T, Dutkowski J, Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell 2011; 144: 860-3.
29. Hwang D, Lee IY, Yoo H et al. A systems approach to prion disease. Mol Syst Biol 2009; 5: 252.
30. Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106: 4402-7.
31. Lin EH, Hassan M, Li Y et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007; 110: 534-42.
32. Iinuma H, Watanabe T, Mimori K et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011; 29: 1547-55.
33. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008; 40: 722-9.
34. Maher CA, Palanisamy N, Brenner JC et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009; 106: 12353-8.
35. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
36. Leary RJ, Kinde I, Diehl F et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2: 20ra14.
37. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
38. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
39. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
40. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
41. Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6.
42. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
43. Price ND, Trent J, El-Naggar AK et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 2007; 104: 3414-9.
44. Yan X, Ma L, Yi D et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 2011; 108: 1591-6.
45. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009; 138: 795-806.
46. Cima I, Schiess R, Wild P et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A 2011; 108: 3342-7.
47. Petriv OI, Kuchenbauer F, Delaney AD et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A 2010; 107: 15443-8.
48. Hood L. Biological Complexity Under Attack, A Personal View of Systems Biology and the Coming of "Big" Science. Genetic Engineering & Biotechnology News, 2011.